Measuring Cost-Effectiveness Of New Medical Technologies
To decide whether a new medical technology is cost effective, researchers often “compar[e] a new technology’s incremental cost-effectiveness ratio or ICER to a threshold that is some multiple of a country or income group’s GDP per capita, per WHO convention,” Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), writes in the CGD’s “Global Health Policy” blog. “In practice however, GDP-based thresholds have little empirical basis, as Shilcutt and co-authors lay out in their excellent review of decision rules and their use in studies related to low- and middle-income countries (LMIC),” she continues and describes the report (2/5).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.